Influence of Acute and Chronic GVHD on Molecular Relapse of CML Leukemia After Allogeneic BMT or PBSCT
| . | BMT . | PBSCT . | P Value* . | ||
|---|---|---|---|---|---|
| Patient No. With MR/ Patient No. With GvHD (%) . | Cumulative 4-yr Estimate of MR . | Patient No. With MR/ Patient No. With GvHD (%) . | Cumulative 4-yr Estimate of MR . | ||
| Acute GVHD | |||||
| Grades 0-I | 17/46 (37) | 47% ± 9% | 2/18 (11) | 13% ± 8% | <.07 |
| Grades II-IV | 3/16 (19) | 28% ± 15% | 0/11 (0) | 0% | NS |
| Chronic GVHD | |||||
| Absent | 6/16 (37) | 63% ± 18% | 1/8 (12) | 17% ± 15% | NS |
| Present | 14/46 (30) | 39% ± 9% | 1/21 (5) | 5% ± 5% | <.03 |
| Acute or chronic GVHD | |||||
| Absent | 6/13 (46) | 65% ± 18% | 1/8 (12) | 17% ± 15% | NS |
| Present | 14/49 (29) | 39% ± 9% | 1/21 (5) | 5% ± 5% | <.03 |
| . | BMT . | PBSCT . | P Value* . | ||
|---|---|---|---|---|---|
| Patient No. With MR/ Patient No. With GvHD (%) . | Cumulative 4-yr Estimate of MR . | Patient No. With MR/ Patient No. With GvHD (%) . | Cumulative 4-yr Estimate of MR . | ||
| Acute GVHD | |||||
| Grades 0-I | 17/46 (37) | 47% ± 9% | 2/18 (11) | 13% ± 8% | <.07 |
| Grades II-IV | 3/16 (19) | 28% ± 15% | 0/11 (0) | 0% | NS |
| Chronic GVHD | |||||
| Absent | 6/16 (37) | 63% ± 18% | 1/8 (12) | 17% ± 15% | NS |
| Present | 14/46 (30) | 39% ± 9% | 1/21 (5) | 5% ± 5% | <.03 |
| Acute or chronic GVHD | |||||
| Absent | 6/13 (46) | 65% ± 18% | 1/8 (12) | 17% ± 15% | NS |
| Present | 14/49 (29) | 39% ± 9% | 1/21 (5) | 5% ± 5% | <.03 |
Abbreviations: MR, molecular relapse; GVHD, graft-versus-host disease.
Significances derived by log-rank test of event distribution functions across strata (BMT v PBSCT).